Regeneron Releases Positive Trial Data For Covid Antibody Treatment As It Seeks Emergency FDA Authorization

Data from 524 patients in a randomized, double-blind trial showed Regeneron’s antibody treatment, REGN-COV2, “significantly reduced viral load and patient medical visits,” Regeneron said. 

Including results from a separate batch of 275 patients in the same trial, Regeneron found REGN-COV2 reduced Covid-19 related medical visits by 57% through day 29 of treatment.

The strong effects were recorded in patients with “poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors,” George D. Yancopoulos, Regeneron’s chief scientific officer, said in a statement.

Though it was used by Trump, the treatment isn’t available to the public because it hasn’t yet been given emergency use authorization from the FDA. 

Regeneron said it submitted the data to the FDA, which is reviewing its EUA application.

Regeneron shares jumped 2.9% in after hours trading following the news.